Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes
Latest Information Update: 03 Nov 2022
At a glance
- Drugs Dapagliflozin (Primary) ; Antihypertensives; Sulfonylureas
- Indications Hypertension in diabetes; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 07 May 2020 Status changed from recruiting to completed.
- 11 Sep 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 11 Sep 2018 Planned primary completion date changed from 1 Mar 2018 to 1 May 2019.